Acceptability of screening to prevent osteoporotic fractures: A qualitative study with older women

Family Practice

Volumn 29, Issue 2, 2012, Pages 235-242

  Emmett, Clare L ^a   Redmond, Niamh M ^a   Peters, Tim J ^a   Clarke, Shane ^b   Shepstone, Lee ^c   Lenaghan, Elizabeth ^c   Shaw, Alison R G ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Aged; Mass screening; Osteoporosis; Qualitative research

Indexed keywords

ADULT; AGED; AGING; ANXIETY; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRAGILITY FRACTURE; GENERAL PRACTITIONER; HUMAN; IMMOBILIZATION; INFORMATION PROCESSING; MASS SCREENING; NORMAL HUMAN; PATIENT ATTITUDE; PATIENT CARE; PHYSICAL ACTIVITY; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEMI STRUCTURED INTERVIEW; THEMATIC ANALYSIS; UNITED KINGDOM;

EID: 84859240557     PISSN: 02632136     EISSN: 14602229     Source Type: Journal    
DOI: 10.1093/fampra/cmr069     Document Type: Article

References (24)

1. National Institute for Health and Clinical Excellence. Alendronate, Etidronate, Risedronate, Raloxifene, Strontium Ranelate and Teriparatide for Secondary Prevention of Osteoporotic Fragility Fractures in Postmenapausal Women. [Amended], London: National Institute for Health and Clinical Excellence, 2008.
2. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6.
3. Roux C, Reginster J-Y, Fechtenbaum J et al. Vertebral fracture risk reduetion with strontium ranelate in women with postmenopausal osteoporosis in independent of baseline risk factors. J Bone Min Res 2006; 21: 536-42.
4. Hodsman AB, Hanley DA, Josse R. Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ 2002; 166: 1426-30.
5. National Institute for Health and Clinical Excellence. Alendronate, Etidronate, Risedronate, Raloxifene and Strontium Ranelate for the Primary Prevention for Health and Osteoporotic Fragility Fractures in Postmenapausal Women. [Amended], London: National Institute for Health and Clinical Excellence, 2008.
6. Compston J, Cooper A, Cooper C et al. Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. www.shef.ac.uk/NOGG/(accessed on 24 August 2011).
7. Verdijk NA, Romeijnders AC, Ruskus JJ, van der Sluijs C, Pop VJ. Validation of the Dutch guidelines for dual X-ray absorptiometry measurement. Br J Gen Pract 2009; 59: 256-60.
8. Cooper A. A fractured service: the latest advice on osteoporosis. Br J Gen Pract 2009; 59: 239-41.
9. Richardson JC, Hassell AB, Thomas E, Hay EM. GPs' perceptions of the role of DEXA scanning: an exploratory study. Fam Pract 2004; 21: 51-3.
10. Manek N. Missed opportunities for osteoporosis management in older patients: a literature review. Prim Health Care Res Dev 2010; 11: 155-65.
11. World Health Organisation FRAX® WHO Fracture Risk Assessment Tool. www.shef.ac.uk/FRAX/(last accessed on 24 August 2011).
12. Eborall HC, Griffin SJ, Prevost AT, Kinmonth A-L, French DP, Sutton S. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. Br Med J 2007; 335: 486-94.
13. Peters TJ, Somerset M, Baxter K, Wilkinson C. Anxiety amongst women with mild dyskaryosis: randomized trial of an educational intervention. Br J Gen Pract 1999; 49: 348-52.
14. Wardle J, Pope R. The psychological costs of screening for cancer. J Psychosom Res 1992; 36: 609-24.
15. Rimes KA, Salkovskis PM, Shipman J. Psychological and behavioural effects of bone density screening for osteoporosis. Psychol Health 1999; 14: 585-608.
16. Rubin SM, Cummings SR. Results of a bone densitometry affect women's decisions about taking measure to prevent fractures. Ann Intern Med 1992; 116: 990-5.
17. Torgerson DJ, Thomas RE, Campbell MK, Reid DM. Randomized trial of osteoporosis screening: use of hormone replacement therapy and quality of life results. Arch Intern Med 1997; 157: 2121-5.
18. Reventlow S, Hvas L, Malterud K. Making the invisible body visible: bone scans, osteoporosis and women's bodily experiences. Soc Sci Med 2006; 62: 2720-31.
19. Richardson JC, Hassell AB, Hay EM, Thomas E. "I'd rather go and know": women's understanding and experience of DEXA scanning for osteoporosis. Health Expect 2002; 5: 114-26.
20. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In Bryman A, Burgess RG (eds). Analyzing Qualitative Data, Oxford, UK: Routledge, 1994: pp. 173-194.
21. Marteau TM, Bekker HL. The development of a six-item shortform of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992; 31: 301-6.
22. Sandelowski M. Whatever happened to qualitative description? Res Nurs Health 2000; 23: 334-40.
23. Beckett LA, Brock DB, Lemke JH et al. Analysis of change is selfreported physical function among older persons in four population studies. Am J Epidemiol 1996; 143: 766-78.
24. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and complicance with bisphosphonates for osteoporosis. Osteoporos Int 2007; 18: 1023-31.